Tirzepatide dosing and titration: the schedule, and what each dose step costs
2.5 mg to 15 mg: the label titration schedule, how long it takes, and the chart showing why flat-rate pricing matters even more for tirzepatide than semaglutide.
The tirzepatide dose ladder
The label is specific: start 2.5 mg once weekly for 4 weeks, then increase to 5 mg, and thereafter increase by 2.5 mg no more often than every 4 weeks. The available maintenance doses are 5 mg, 10 mg, and 15 mg. The 2.5 mg starting dose is explicitly for treatment initiation and is not intended as a therapeutic dose. The escalation exists to reduce gastrointestinal side effects; if a dose isn't tolerated, prescribers may hold or slow the increase. Reaching the 15 mg maximum takes at least 20 weeks on the standard schedule.
| Dose step | Duration | Earliest week | Note |
|---|---|---|---|
| 2.5 mg (start) | 4 weeks | Week 1 | Initiation; not therapeutic |
| 5 mg | 4+ weeks | Week 5 | First maintenance option |
| 7.5 mg | 4+ weeks | Week 9 | Escalation |
| 10 mg | 4+ weeks | Week 13 | Maintenance option |
| 12.5 mg | 4+ weeks | Week 17 | Escalation |
| 15 mg (max) | ongoing | Week 21 | Highest maintenance dose |
How long titration realistically takes
The standard schedule reaches 15 mg at about 20–24 weeks, but many prescribers go slower for patients with side effects, and some maintain effectively at 5 or 10 mg if that's where they tolerate and respond well. The goal is the maximum tolerated effective dose, not necessarily the label maximum — though because SURMOUNT-1 showed more weight loss at higher doses, many patients and prescribers do aim for 10 or 15 mg.
What each dose step costs — where pricing model matters
On a flat-rate plan the dose ladder is clinically driven; on dose-tiered plans, every rung costs money. And tirzepatide makes this trap sharper than semaglutide, because efficacy rises with dose, so patients are pulled toward the expensive top of the ladder. At typical dose-tiered prices, reaching and maintaining 15 mg can add $150–$250/month versus the starting dose — and you spend most of your treatment life at maintenance.
Why higher doses matter more for tirzepatide pricing
Tirzepatide's dosing story has a financial twist that semaglutide's doesn't. With semaglutide, the therapeutic target for weight management is a single maintenance dose (2.4 mg). With tirzepatide, there are three approved maintenance doses (5, 10, 15 mg), and the trial data show a clear dose-response: more weight loss at higher doses. That means the clinical incentive pushes many patients toward 10 or 15 mg — exactly where dose-tiered pricing is most expensive. On a dose-tiered plan, the pursuit of maximum efficacy directly raises your monthly cost, and the two goals pull against each other. On a flat-rate plan they don't: you can titrate to the most effective tolerated dose without watching the price climb. This is the underrated reason flat-rate pricing is especially valuable for tirzepatide specifically — it removes the cost penalty from chasing the dose-response the trials demonstrated. When comparing tirzepatide programs, always ask for the price at 15 mg, not the 2.5 mg starter rate, because that top-of-ladder number is where most of your treatment life and most of your spending will actually happen. Dosing itself always remains a decision for your prescriber.
Frequently asked questions
What is the tirzepatide dosing schedule?
Start at 2.5 mg once weekly for 4 weeks, then increase by 2.5 mg no more often than every 4 weeks (5, 7.5, 10, 12.5, 15 mg). Approved maintenance doses are 5, 10, and 15 mg. The escalation reduces gastrointestinal side effects.
How long to reach the full tirzepatide dose?
The standard schedule reaches 15 mg at about 20–24 weeks. Many prescribers titrate more slowly based on tolerability, and some maintain effectively at 5 or 10 mg.
Does tirzepatide dose affect monthly cost?
On flat-rate pricing: no — you pay the same at 2.5 mg and 15 mg. On dose-tiered pricing: yes — reaching 15 mg (where efficacy is highest and most patients aim) can cost $150–$250/month more than the starter price.
What is the tirzepatide maintenance dose?
The approved maintenance doses are 5, 10, and 15 mg once weekly. Trial data show more weight loss at higher doses, but the right dose is a clinical decision balancing efficacy and tolerability with a prescriber.
Three dosing questions that change the financial picture
The dose ladder is where pricing structure quietly determines your total tirzepatide cost, so three specific questions before enrollment surface the hidden math that a starter price conceals. First, ask what you will pay per month at 15 mg, not at 2.5 mg. This is the number that matters, because the trial data pull most patients toward the higher, more effective doses, and on a dose-tiered plan the 15 mg price can be $150-250 a month above the advertised entry rate. Second, ask whether there is any extra charge to pause or slow your titration. Because side effects cluster at dose increases and some patients need to hold a dose longer, a plan that charges for flexibility penalizes exactly the patients who need it most; a good program builds slowing into the standard of care at no extra cost. Third, ask whether a dose-change consultation costs extra, since some programs bill a separate visit fee every time your dose is adjusted, turning the normal six-step titration into a series of billable events. On a bundled flat-rate plan, the answers to all three tend to be favorable: one price across every dose, no penalty to slow down, visits included, which is the practical reason flat-rate structures often produce the lowest real cost for tirzepatide specifically despite not always having the lowest headline number. Asking these three questions before you pay converts an opaque comparison into a clear one, and it costs nothing but a few minutes. Dosing itself always remains a decision for your prescriber, who will balance the dose-response evidence against your individual tolerability.
References
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information — dosing and administration.
- Jastreboff AM, et al. SURMOUNT-1 dose-response data. N Engl J Med. 2022.
- WeightLoss GLP-1 July 2026 price report and trends page.
- U.S. FDA. Communications on dosing errors with compounded products.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.